Giant Biogene Holding Co (HKSE:02367) Change In Receivables : HK$-36 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Change In Receivables?

Giant Biogene Holding Co's change in receivables for the quarter that ended in Dec. 2023 was HK$-12 Mil. It means Giant Biogene Holding Co's Accounts Receivable increased by HK$12 Mil from Jun. 2023 to Dec. 2023 .

Giant Biogene Holding Co's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-36 Mil. It means Giant Biogene Holding Co's Accounts Receivable increased by HK$36 Mil from Dec. 2022 to Dec. 2023 .

Giant Biogene Holding Co's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$89 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Giant Biogene Holding Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 7.72.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Giant Biogene Holding Co's liquidation value for the six months ended in Dec. 2023 was HK$3,651 Mil.

Giant Biogene Holding Co Change In Receivables Historical Data

The historical data trend for Giant Biogene Holding Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Change In Receivables Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-49.61

102.09

-13.67

-4.06

-35.64

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	10.69	-14.24	-23.26	-12.38

Giant Biogene Holding Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-36 Mil.

Giant Biogene Holding Co (HKSE:02367) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Giant Biogene Holding Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	88.725	/	2098.355	*	91
=	7.72

2. In Ben Graham's calculation of liquidation value, Giant Biogene Holding Co's accounts receivable are only considered to be worth 75% of book value:

Giant Biogene Holding Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4133.144	-	658.486	+	0.75 * 88.725	+	0.5 * 219.237
=	3,651

Giant Biogene Holding Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines